Acquired in 2007 by Cytyc Corporation, a leading global women's health company, .Adeza Biomedical is focused to diagnostic products and services targeted to women's health care - primarily the diagnosis of pregnancy-related and female reproductive disorders, including preterm birth, preeclampsia, endometriosis and infertility. Adeza manufactures, sells and markets Fetal-Fibronectin ELISA (immunoassay) for assessing a pregnant woman's risk for delivering prematurely. The firm has FDA system for rapid Fetal Fibronectin testing - the TLi(tm) System - one hour turnaround test. Adeza designs, manufactures and markets innovative products for women's health. Adeza's initial focus is on reproductive healthcare, using its proprietary technologies to predict preterm birth and assess infertility. Adeza's principal product is a patented diagnostic test, Full Term, The Fetal Fibronectin Test, which utilizes a single-use, disposable cassette and is analyzed on Adeza's patented TLiIQ(R) System. This product is approved by the U.S. Food and Drug Administration (FDA) for broad use in assessing the risk of preterm birth. Adeza also markets and sells the E-tegrity(R) Test, an infertility-related test to assess receptivity of the uterus to embryo implantation in women with unexplained infertility.
